Explore All 595 Divestiture Healthcare Services Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 7, 2016 |
| Target | Lonza Group AG - Peptides Business and Operations |
| Sector | Healthcare Services |
| Buyer(s) | PolyPeptide Group |
| Sellers(s) | Lonza |
| Deal Type | Divestiture |
FILTER BY
PolyPeptide Group is a manufactuer of biotechnology products in Sweden.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Healthcare Services | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: Belgium | 1 of 1 |
| Year: 2016 | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1897 |
| Sector | Life Science |
| Employees | 18,000 |
| Revenue | 6.6B CHF (2024) |
Lonza is a global company that focuses on the life sciences sector, offering products and services for the pharmaceutical, biotech, and nutrition markets. Their portfolio spans across biopharmaceutical development and manufacturing, consumer health, nutrition, microbial control solutions, and custom manufacturing of specialty chemicals. Lonza was founded in 1897 and is based in Basel, Switzerland.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 5 |
| Sector: Healthcare Services | 1 of 1 |
| Type: Divestiture | 1 of 5 |
| Country: Belgium | 1 of 1 |
| Year: 2016 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-08-15 |
InterHealth Nutraceuticals
Benicia, California, United States InterHealth Nutraceuticals, Inc. is a provider in research, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. |
Buy | $300M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-12-15 |
Capsugel Belgium NV
Colmar, France Capsugel Belgium NV is a provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries. Capsugel offers a comprehensive array of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to innovative R&D equipment and liquid formulations as part of its Licaps Drug Delivery System. |
Buy | $5.5B |
